Physician

Cassandra J Lacher, DO

According to 2025 Medicare claims, Cassandra Lacher, DO (NPI: 1467746651) practices medical oncology in the Kankakee, IL market, with the plurality of this provider's patient population coming from Kankakee, IL. This provider's primary affiliated billing organization is RIVERSIDE HEALTH SYSTEM (NPI: 1417061193; TIN: 36-3167726) and primary practice location at 60914-4689. Lacher is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Lacher's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 425 traditional Medicare patients, billed 1,498 HCPCS/CPT codes, and received $79,710 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,873 prescription claims across 330 beneficiaries totaling $2,924,569 in drug costs, led by Xtandi (Enzalutamide). DME data shows 11 claims. Open Payments data shows 25 records totaling $554. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $15,373 to $2,924,569. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,628 to $751.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	386	987	$76,345
2016	136	243	$15,960
2017	115	218	$14,326
2018	135	208	$12,456
2019	333	720	$44,918
2020	380	835	$57,270
2021	369	830	$71,082
2022	392	888	$71,370
2023	321	781	$66,664
2024	425	1,498	$79,710

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	137	336	$15,373
2016	49	163	$68,048
2017	52	201	$74,395
2018	70	214	$210,519
2019	146	682	$624,407
2020	200	1,340	$1,268,732
2021	212	1,255	$1,928,185
2022	219	1,345	$2,324,213
2023	252	1,096	$1,568,079
2024	330	1,873	$2,924,569

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	44	$4,308
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$2,804
2020	N/R	N/R	N/R
2021	N/R	88	$45,327
2022	N/R	34	$2,244
2023	N/R	26	$2,989
2024	N/R	11	$113

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	65	65	$128
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	71	95	$101
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	59	59	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	327	676	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	287	529	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	25	750	$336,780
Revlimid	Lenalidomide	21	581	$322,841
Jakafi	Ruxolitinib Phosphate	24	720	$277,186
Brukinsa	Zanubrutinib	15	450	$216,315
Nubeqa	Darolutamide	13	390	$120,970

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$113

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$554	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Cassandra J. Lacher, DO?

Tedicare shows public-source Medicare data for Cassandra J. Lacher, DO (NPI 1467746651), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Cassandra J. Lacher, DO have ACO affiliation data?

Cassandra J. Lacher, DO is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Cassandra J. Lacher, DO?

Cassandra J. Lacher, DO is linked to RIVERSIDE HEALTH SYSTEM (billing NPI 1417061193) in the available physician profile data.

Does Cassandra J. Lacher, DO have Open Payments data?

Cassandra J. Lacher, DO has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.